A Phase 1, Single Dose Open-label Study To Evaluate The Pharmacokinetics Of Lorlatinib In Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Lorlatinib (Primary)
- Indications Lymphoma; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 Planned End Date changed from 13 Feb 2020 to 11 Apr 2020.
- 04 Jul 2018 Planned primary completion date changed from 16 Jan 2020 to 14 Mar 2020.